Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...207208209210211212213214215216217...10661067»
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Journal:  Lumbosacral Radiculoplexus Neuropathy After COVID-19. (Pubmed Central) -  Feb 3, 2023   
    Trial completion date: Sep 2023 --> Feb 2026 | Trial primary completion date: Jan 2023 --> Feb 2026 COVID-19 can trigger postinfectious inflammatory neuropathies including LRPN.
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion date, Trial primary completion date:  HAT for the Treatment of Sepsis Associated With NASTI (clinicaltrials.gov) -  Feb 2, 2023   
    P1/2,  N=132, Recruiting, 
    COVID-19 can trigger postinfectious inflammatory neuropathies including LRPN. Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Sep 2022 --> Sep 2024
  • ||||||||||  hydrocortisone / Generic mfg.
    New trial:  Effects of RF Microneedle on Photoaging Skin (clinicaltrials.gov) -  Feb 2, 2023   
    P=N/A,  N=15, Completed, 
  • ||||||||||  gabapentin / Generic mfg., dexamethasone injection / Generic mfg.
    Retrospective data, Review, Journal:  Orthostatic Intolerance-Type Events Following Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Feb 2, 2023   
    OI-type events are common during the acute hospital stay following hip and knee arthroplasty, and 4 risk factors have been reported for OI-type events. High-quality prospective cohort studies are required to systematically and reliably determine the incidence of and risk factors for OI-type events.
  • ||||||||||  Korlym (mifepristone) / Corcept Therap
    Trial primary completion date, Metastases:  Abraxane (clinicaltrials.gov) -  Feb 2, 2023   
    P2,  N=64, Active, not recruiting, 
    High-quality prospective cohort studies are required to systematically and reliably determine the incidence of and risk factors for OI-type events. Trial primary completion date: Aug 2021 --> Dec 2022
  • ||||||||||  Veramyst (fluticasone furoate nasal spray) / GSK
    Trial completion date, Trial primary completion date:  ACTIV-6: COVID-19 Study of Repurposed Medications (clinicaltrials.gov) -  Feb 2, 2023   
    P3,  N=15000, Recruiting, 
    Trial primary completion date: Aug 2021 --> Dec 2022 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Pre-emptive Dexamethasone in Hip Arthroplasty (clinicaltrials.gov) -  Feb 2, 2023   
    P=N/A,  N=83, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Sep 2022 --> Jan 2023
  • ||||||||||  Benlysta (belimumab) / GSK
    Journal:  Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series. (Pubmed Central) -  Feb 1, 2023   
    In primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) and fibrates have improved prognosis dramatically, but there remains a proportion of patients with refractory disease.In patients with refractory AIH and/or PBC, we used a novel treatment strategy with the anti-B cell activating factor, belimumab...In PBC however, response was not convincing. The effects on sicca symptoms and fatigue were encouraging.
  • ||||||||||  hydrocortisone / Generic mfg., epinephrine / Generic mfg.
    Journal:  Akutt binyrebarksvikt hos et barn. (Pubmed Central) -  Feb 1, 2023   
    Acute adrenal crisis is a rare primary presentation of adrenal insufficiency, especially in the paediatric population. It is an important differential diagnosis of shock and has high morbidity and mortality.
  • ||||||||||  budesonide / Generic mfg.
    Journal:  Minimalist Nanocomplex with Dual Regulation of Endothelial Function and Inflammation for Targeted Therapy of Inflammatory Vascular Diseases. (Pubmed Central) -  Feb 1, 2023   
    Inspired by the vascular regulatory versatility of nitric oxide (NO) produced by endothelial nitric oxide synthase (eNOS) catalyzing l-arginine (l-Arg), the eNOS-activating effects of l-Arg, and the powerful anti-inflammatory and eNOS-replenishing effects of budesonide (BUD), we constructed a bi-prodrug minimalist nanoplatform co-loaded with BUD and l-Arg via polysialic acid (PSA) to form BUD-l-Arg@PSA...In an atherosclerosis mouse model, BUD-l-Arg@PSA decreased atherosclerotic plaque burden and improved vasodilation. This represents a revolutionary therapeutic strategy for inflammatory vascular diseases.
  • ||||||||||  budesonide / Generic mfg., methotrexate / Generic mfg.
    Ileocecal valve that cannot be intubated during colonoscopy in patients with Crohn's disease: Is this a sign of poor prognosis? (Poster exhibition) -  Feb 1, 2023 - Abstract #ECCOIBD2023ECCO_IBD_966;    
    Budesonide (37 vs. 13; p=0.043) and methotrexate use (32 vs. 9; p=0.017) was more common the intubated group, while 5-ASA, steroid, and thiopurine use was similar. Non-intubated group had higher rates of steroid dependence (67.2% vs. 46.4%; p=0.012), biologic treatment (89.7% vs. 58.8%; p<0.001), CD-related hospitalization (81% vs. 24.7%; p<0.001), and major abdominal surgery (58.6% vs. 15.5%; p<0.001).In logistic regression analysis, positive predictors of successful ileum intubation were inflammatory type CD (OR: 14.821), high serum albumin level (OR: 5.919), and older age (OR: 1.069), whereas negative predictors were stenosing (OR: 0.262) and penetrating (OR: 0.247) CD behavior.ConclusionIn CD patients with isolated ileal involvement, the inability to intubate the ileocecal valve during colonoscopy may indicate a poor prognosis.
  • ||||||||||  budesonide / Generic mfg., methotrexate / Generic mfg.
    Calcitonin gene related peptide beta (CGRPβ): a new player in inflammatory bowel disease pathophysiology (Poster exhibition) -  Feb 1, 2023 - Abstract #ECCOIBD2023ECCO_IBD_687;    
    The results are illustrated in figures 1 and 2.ConclusionThe consistent decrease in CGRPβ levels in IBD shown here strongly supports a protective role of this peptide in the homeostasis of the intestinal mucosa. This work was supported by a grant from the Instituto de Salud Carlos III (PI20/01358).
  • ||||||||||  abiraterone acetate / Generic mfg.
    Enrollment change, Trial withdrawal:  ARCH: Androgen Reduction in Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Feb 1, 2023   
    P2,  N=0, Withdrawn, 
    This work was supported by a grant from the Instituto de Salud Carlos III (PI20/01358). N=54 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  relacorilant (CORT125134) / Corcept Therap
    ROSELLA  () -  Feb 1, 2023 - Abstract #SGO2023SGO_454;    
  • ||||||||||  dexamethasone / Generic mfg., paracetamol / Generic mfg.
    Journal:  Improving human mesenchymal stem cell-derived hepatic cell energy metabolism by manipulating glucose homeostasis and glucocorticoid signaling. (Pubmed Central) -  Jan 31, 2023   
    Ammonia detoxification, EROD and UGT activities and sensitivity to paracetamol cytotoxicity were also enhanced under more physiologically relevant conditions. HLCs kept under reduced concentrations of glucose, insulin and dexamethasone presented an improved hepatic phenotype and insulin sensitivity demonstrating superior potential as an in vitro platform for modeling energy metabolism-related disorders, namely for the investigation of the insulin signaling pathway.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Outcome of COVID-19 infections in patients with adrenal insufficiency and excess. (Pubmed Central) -  Jan 31, 2023   
    This European multicentric questionnaire is the first to collect data on the outcome of COVID-19 infection in patients with adrenal gland disorders. It suggests good clinical outcome in case of duly dose adjustments and emphasizes the importance of patient education on sick day rules.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., pomalidomide / Generic mfg.
    Enrollment open:  PVd Versus Vd in NDMM Patients With RI (clinicaltrials.gov) -  Jan 31, 2023   
    P2,  N=79, Recruiting, 
    Trial completion date: Nov 2022 --> Nov 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Xpovio (selinexor) / Karyopharm
    Enrollment closed, Combination therapy:  STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov) -  Jan 31, 2023   
    P1b/2,  N=518, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting